ReviewHealth economics review2024

Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review.

Hongyu Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.